Metformin does not prevent atherosclerotic cardiovascular disease

Craig D Williams*

Oregon State University/ OHSU College of Pharmacy, USA

Abstract

The recent description of the cellular mechanism of action of metformin offers the opportunity to re-visit the question of whether or not metformin is beneficial in patients with atherosclerotic cardiovascular disease (ASCVD)[1]. In the 2012 consensus statement on managing hyperglycemia, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) state that metformin "may have some cardiovascular benefits and would appear to be a useful drug in the setting of CAD." [2] This opinion is popular in clinical practice. The single citation offered by ADA/EASD in support of a cardiovascular benefit of metformin is the UK Prospective Diabetes Study (UKPDS) [3]. But the UKPDS was a complicated trial with varying degrees of glycemic control across multiple substudies [3-6]. The results are also now nearly 2 decades old and our understanding of the impact of glycemic control on atherosclerosis has evolved. It is thus fair to ask again whether or not metformin has any antiatherogenic properties aside from its antihyperglycemic effects.

The UKPDS began recruiting patients in 1977, just several years after the publication of the University Group Diabetes Program trial (UGDP). The UGDP trial was specifically designed to study the vascular effects of antihyperglycemic therapies in patients with adult-onset diabetes [7]. In addition to tolbutamide and insulin, UGDP used phenformin, a biguanide similar to metformin. In a surprise finding, the phenformin arm was stopped early when a preliminary analysis of study data showed a fourfold increase in cardiovascular death compared to placebo (12.7% vs. 3.1%, p=0.04) [8]. Compared to the insulin arms of the trial, phenformin had a nearly twofold increase in cardiovascular death although this finding was not statistically significant (12.7% vs. 6.8%, p=0.11) [8].

The adverse cardiovascular outcomes with phenformin were an understandable cause of some concern for metformin. Thus when UKPDS began recruiting just six years after the publication of the phenformin findings of UGDP, it did so with a complicated protocol involving two different metformin substudies, one of monotherapy and one as a sulfonylurea add-on.

The monotherapy trial enrolled only overweight patients (n=1,704 with 342 assigned metformin) while the sulfonylurea add-on arm enrolled the 13% of the study population who failed to achieve their "tight" glycemic goal on sulfonylurea monotherapy (n=567 with 268 assigned metformin).[3] The findings of these substudies was that metformin monotherapy was associated with a 39% reduction in myocardial infarction (p=0.01) and a 36% reduction in all-cause mortality (p=0.01) while metformin add-on therapy was associated with a 60% increase in all-cause mortality (p=0.04) including a non-significant 79% increase in fatal myocardial infarction (11.0% vs. 6.2%, p=0.14).

So, a combined analysis of the clinical endpoints of the UGDP and UKPDS suggests that in patients with adult-onset diabetes, phenformin increases CV death while metformin increases mortality when added to a sulfonylurea but reduces mortality and myocardial infarction when used as monotherapy in overweight patients. Given these apparent contradictions, does the new understanding of the mechanism of action of metformin offer any insight into whether it could be anti-atherogenic, pro-atherogenic or both?

In an elegant series of experiments published in 2014, metformin was found to inhibit a mitochondrial enzyme in hepatocytes which affects the ratio of cytosolic NADH-NAD [9]. This results in an inhibition of the conversion of lactate to pyruvate which subsequently impairs hepatic gluconeogenesis. Could this molecular mechanism plausibly affect the initiation or progression of ASCVD?

Atherosclerosis is well understood to be a process of vascular inflammation in response to the retention of atherogenic lipoprotein particles in the artery wall [10]. While patients with diabetes are well known to have a higher rate of ASCVD events compared to patients without diabetes, the etiology is this greater atherosclerotic burden is multifactorial and the role of hyperglycemia remains controversial [11]. However, a drug which inhibits a hepatic enzyme to reduce gluconeogenesis would not seem to offer any direct benefit on the
known processes of atherosclerosis. While it is possible that additional mechanisms of action will be discovered for metformin, that is unlikely given the elegant experiments that led to the current discovery [1]. If the mechanism of action of metformin makes it unlikely that it offers any direct antiatherogenic benefit, what might explain the apparent benefit in the monotherapy arm of the UKPD? 

Importantly, the metformin monotherapy arm of UKPDS compared intensive therapy with metformin to conventional therapy with diet [3]. Two important aspects of this design could have falsely accounted for the apparent ASCVD benefit of metformin.

First, glycemic control was improved with “intensive” metformin therapy (median daily dose 2550 mg) compared to the conventional dietary group. During the first 5 years of follow-up, A1C averaged 6.7% in the metformin group compared to 7.5% in the conventional group [3]. Over the 10 years of follow-up, A1C averaged 7.5% in the metformin group compared to 8.0% in the conventional group. While these differences are not large, they should not be discounted. Recent trials which have examined the relationship between glycemic control and ASCVD have found consistent trends for reductions in ASCVD events with reductions in A1C [11-15]. In the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes Study Group), an A1C of 6.4% compared to 7.5% was associated with a non-significant 10% risk reduction in the composite endpoint of non-fatal MI, non-fatal stroke and CVD death and a significant 24% risk reduction in non-fatal MI [12].

Second, while there were no major hypoglycemic episodes in the metformin monotherapy arm of UKPDS, the conventional comparator group had a rate of major hypoglycemic episodes of 0.7% per year [3]. While it may seem implausible that a dietary control group would have episodes of major hypoglycaemia, a closer look at the design of UKPDS reveals that 44% of that cohort could not meet their glycemic goal on diet alone and received supplemental therapies, primarily with sulfonylureas and insulin [3] .These are agents which are well known to carry a risk of major hypoglycemia.

Increased mortality risk attributable to hypoglycemia is an area of increasing interest among the diabetes community [16-19]. In the newer trials which examined the relationship between glycemic control and clinical outcomes, trends for total mortality are increased despite trends for reductions in cardiovascular events [11,15]. Strong associations have been found between episodes of hypoglycemia and mortality, a relationship which may be explained by arrhythmias and sudden cardiac death [16,19].

Last, it should be noted that the pharmacokinetics of metformin also argue against a direct ASCVD benefit. While metformin is found in high concentrations in the gut wall and liver, it is found in very small concentrations in the plasma and other tissue, including cardiac and vascular [20].

So while the newly described mechanism of action of metformin does not appear to offer an explanation for the apparent ASCVD benefits seen in the monotherapy arm of the UKPDS, the complicated design of that trial itself does offer an explanation. In the context of our current understanding of the relationships between glycemic control, atherosclerosis and mortality, improving glycemic control without any major episodes of hypoglycemia could well account for the apparent benefit of metformin in the monotherapy arm of UKPDS. A lack of direct ASCVD benefit from metformin would also explain why benefits were not seen in the metformin add-on arm in UKPDS. So while metformin remains a great first line choice for glycemic control in most of our patients with diabetes, it is time to stop thinking about it as an antiatherogenic drug.

References
15. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP et al. (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes care 33: 983-990. [Crossref]

Copyright: ©2017 Williams CD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.